---
title: Enhanced Procoagulant Activity of Select Hemophilia B Causing Factor IX Variants
  with Emicizumab
date: '2024-07-10'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38985830/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240711181424&v=2.18.0.post9+e462414
source: Blood
description: Emicizumab improves the procoagulant activity of select loss-of-function
  FIX variants with likely dysfunctional assembly of the intrinsic Xase complex that
  cause hemophilia B. FVIII-mimetics may represent an alternative non-factor therapy
  for select hemophilia B ...
disable_comments: true
---
Emicizumab improves the procoagulant activity of select loss-of-function FIX variants with likely dysfunctional assembly of the intrinsic Xase complex that cause hemophilia B. FVIII-mimetics may represent an alternative non-factor therapy for select hemophilia B ...